ReviewJournal of translational medicine2017
The spleen in liver cirrhosis: revisiting an old enemy with novel targets.
Review in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.
- Diagnosis of Liver Fibrosis Using Artificial Intelligence: A Systematic Review.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Comparison of apixaban and warfarin in preventing portal vein system thrombosis after laparoscopic splenectomy for cirrhotic patients with secondary hypersplenism: a randomized controlled trial.Surgical endoscopy · 2026Trial
- Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.Journal of gastroenterology · 2023Trial
- Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial.Hepatology international · 2021Trial
- Hepatitis B virus RNA levels and clinical characteristics of persistent viremia in HBsAg-positive patients undergoing nucleos(t)ide analog.Virus research · 2026Article
- Anti-Angiogenic Features of Endostatin in Obesity, Liver Fibrosis, and Hepatocellular Carcinoma.Biomedicines · 2026Review
- Evaluation of Sharpunkha's Efficacy in Splenomegaly- A Research Report.Journal of pharmacy & bioallied sciences · 2026Article
- The Spleen Promotes Liver Sinusoidal Endothelial Cell Angiogenesis by Stimulating the TGFβ/Smad2/3 Pathway Through GDF15.Journal of gastroenterology and hepatology · 2026Article
- Atraumatic Spontaneous Splenic Rupture Complicating Decompensated Chronic Liver Disease With Portal Hypertension: A Case Report.Case reports in radiology · 2026Article
- Development and Validation of a Modality-Invariant 3D Swin U-Net Transformer for Liver and Spleen Segmentation on Multi-Site Clinical Bi-parametric MR Images.Journal of imaging informatics in medicine · 2025Article
- Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical Model.Journal of clinical and translational hepatology · 2025Article
- Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation.Medical sciences (Basel, Switzerland) · 2025Review
- Salvianolic Acid B Alleviates LPS-Induced Spleen Injury by Remodeling Redox Status and Suppressing NLRP3 Inflammasome.Antioxidants (Basel, Switzerland) · 2025Article
- Splenic Artery Ligation: Effects on Portal Flow and Hypersplenism in Living Donor Liver Transplantation.Annals of transplantation · 2025Article
- Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes.Nature communications · 2025Article
- Spontaneous splenic rupture associated with Q fever and portal hypertension: A case report.Frontiers in medicine · 2025Article
- Spleen Volume Dynamics and Survival Outcomes in HCC Patients Undergoing Immune Checkpoint Inhibitors: A Retrospective Analysis.Journal of hepatocellular carcinoma · 2025Article
- Cellular effects of splenectomy on liver regeneration after 70% resection.Frontiers in cell and developmental biology · 2025Article
- The impact of hepatic and splenic volumetric assessment in imaging for chronic liver disease: a narrative review.Insights into imaging · 2024Review
- Enhancing liver cirrhosis varices and CSPH risk prediction with spleen stiffness measurement using 100-Hz probe.Scientific reports · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spleen is a secondary lymphoid organ which can influence the progression of multiple diseases, notably liver cirrhosis. In chronic liver diseases, splenomegaly and hypersplenism can manifest following the development of portal hypertension. These splenic abnormalities correlate with and have been postulated to facilitate the progression of liver fibrosis to cirrhosis, although precise mechanisms remain poorly understood. In this review, we summarize the literature to highlight the mechanistic contributions of splenomegaly and hypersplenism to the development of liver cirrhosis, focusing on three key aspects: hepatic fibrogenesis, hepatic immune microenvironment dysregulation and liver regeneration. We conclude with a discussion of the possible therapeutic strategies for modulating splenic abnormalities, including the novel potential usage of nanomedicine in non-surgically targetting splenic disorders for the treatment of liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.